The approval follows an accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP).
Daklinza
in vitro
Daklinza,
Daklinza
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Commission has approved (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (), for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus (HCV) infection in adults. when used in combination with sofosbuvir, is an all-oral, interferon-free regimen that provided cure rates of up to 100% in clinical trials, including patients with advanced liver disease, genotype 3 and those who have previously failed treatment with protease inhibitors. is the first NS5A complex inhibitor approved in the European Union (EU) and will be available for use in combination with other medicinal products, providing a shorter treatment duration (12 or 24 weeks) compared to 48 weeks of treatment with interferon- and ribavirin-based regimens.
Press release: http://bit.ly/1ooINJl
Source: BMS
HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users
April 17th 2020Despite being at an increased risk for HIV and hepatitis C, persons who inject drugs (PWID) are tested at dismal rates for both: just 8.6% and 7.7%, respectively, according to data from 2010 to 2017. PWID who live in rural communities are more likely to face barriers to adequate testing and care for both diseases.
Read More
Dr Rebekah Gee Offers an Inside Look at Louisiana's Subscription Payment Model for HCV Drugs
May 7th 2019We speak with Dr Rebekah Gee, secretary of the Louisiana Department of Health about the subscription payment model for hepatitis C virus drugs that the state has entered into with Asegua Therapeutics, a subsidiary of Gilead Sciences.
Listen